Potassium hydroxide 5% for the treatment of molluscum contagiosum.

Abstract

Molluscum contagiosum is a common reason for consultation in primary care. The condition is normally benign and self-limiting1 and the standard advice is to wait for the lesions to resolve spontaneously.2 Recently, potassium hydroxide 5% (MolluDab-Alliance Pharmaceuticals Limited) has been marketed in the UK for the treatment of the condition.3 It is sold as a medical device rather than a licensed medicinal product. Here we consider the evidence for potassium hydroxide 5% in the management of molluscum contagiosum.

• Journal: Drug and therapeutics bulletin (Drug Ther Bull) Vol. 52 Issue 10 Pg. 118-20 (Oct 2014) ISSN: 1755-5248 [Electronic] England
• PMID: 25298120 (Publication Type: Journal Article)
• Copyright: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Chemical References

• Hydroxides
• Potassium Compounds
• potassium hydroxide

Topics

• Administration, Cutaneous
• Humans
• Hydroxides (administration & dosage, adverse effects, therapeutic use)
• Molluscum Contagiosum (drug therapy)
• Potassium Compounds (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome